EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise

 
• By Tina Tan

Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.

MT1805_Eiffel Tower_710380270 _1200
EuroPCR 2018 is held in Paris, France between May 22-25

More from Cardiology

More from Device Area